Institut für Neurowissenschaften und Medizin, INM-5: Institut für Nuklearchemie, Forschungszentrum Jülich GmbH, D-52425 Jülich, Germany.
Nucl Med Biol. 2010 Oct;37(7):727-40. doi: 10.1016/j.nucmedbio.2010.04.185.
Positron emission tomography (PET) is a rapidly expanding clinical modality worldwide thanks to the availability of compact medical cyclotrons and automated chemistry for the production of radiopharmaceuticals. There is an armamentarium of fluorine-18 ((18)F) tracers that can be used for PET studies in the fields of oncology and neurosciences. However, most of the (18)F-tracers other than 2-deoxy-2-[18F]fluoro-D-glucose (FDG) are in less than optimum human use and there is considerable scope to bring potentially useful (18)F-tracers to clinical investigation stage. The International Atomic Energy Agency (IAEA) convened a consultants' group meeting to review the current status of (18)F-based radiotracers and to suggest means for accelerating their use for diagnostic applications. The consultants reviewed the developments including the synthetic approaches for the preparation of (18)F-tracers for oncology and neurosciences. A selection of three groups of (18)F-tracers that are useful either in oncology or in neurosciences was done based on well-defined criteria such as application, lack of toxicity, availability of precursors and ease of synthesis. Based on the recommendations of the consultants' group meeting, IAEA started a coordinated research project on "Development of (18)F radiopharmaceuticals (beyond [(18)F]FDG) for use in oncology and neurosciences" in which 14 countries are participating in a 3-year collaborative program. The outcomes of the coordinated research project are expected to catalyze the wider application of several more (18)F-radiopharmaceuticals beyond FDG for diagnostic applications in oncology and neurosciences.
正电子发射断层扫描（PET）是一种在全球范围内迅速发展的临床模式，这要归功于紧凑型医用回旋加速器的可用性和用于放射性药物生产的自动化化学技术。有一系列氟-18（（18）F）示踪剂可用于肿瘤学和神经科学领域的 PET 研究。然而，除了 2-脱氧-2-[18F]氟代-D-葡萄糖（FDG）之外，大多数（18）F 示踪剂的人体应用效果并不理想，有相当大的空间可以将潜在有用的（18）F 示踪剂推向临床研究阶段。国际原子能机构（IAEA）召集了一次顾问小组会议，审查（18）F 基放射性示踪剂的现状，并提出加速其用于诊断应用的方法。顾问们审查了包括为肿瘤学和神经科学制备（18）F 示踪剂的合成方法在内的进展。根据明确的标准，如应用、缺乏毒性、前体的可用性和合成的容易程度，选择了三组在肿瘤学或神经科学中有用的（18）F 示踪剂。根据顾问小组会议的建议，IAEA 启动了一个关于“开发（18）F 放射性药物（超越 [（18）F] FDG）用于肿瘤学和神经科学”的协调研究项目，该项目有 14 个国家参与了一个为期 3 年的合作计划。协调研究项目的结果预计将促进更广泛地应用几种超越 FDG 的（18）F 放射性药物，用于肿瘤学和神经科学的诊断应用。
